We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TNB-383B

News List

AbbVie Exercises Right to Acquire TeneoOne and TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple Myeloma americanpharmaceuticalreview
June 25, 2021
AbbVie and Teneobio, Inc. announced that AbbVie exercised its exclusive right to acquire TeneoOne, an affiliate of Teneobio, Inc., and TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of relapsed or refractory multiple myeloma ...
AbbVie and Teneobio to co-develop new drug for multiple myeloma pharmaceutical-technology
February 13, 2019
AbbVie has entered a strategic collaboration with biotechnology company Teneobio and its affiliate TeneoOne for the development and commercialisation of a multiple myeloma candidate TNB-383B.....